8-K/A: STAAR Surgical Rehires Former CEO David Bailey as CCO

STAAR Surgical announced the appointment of David Bailey, former CEO, as Chief Commercial Officer to drive growth and capitalize on the EVO ICL's market position.

Summary

• STAAR Surgical has appointed David Bailey as its new Chief Commercial Officer, effective September 8, 2026.
• Mr. Bailey previously served as STAAR's CEO from 2001-2008 and President of International Operations from 2008-2011.
• His compensation includes a base salary of CHF 462,825 (approx. $575,000), a target bonus of 60% of base salary, and significant equity awards.
• The equity awards include an initial grant valued at $850,000 (50% RSUs, 50% stock options) and a 2026 long-term incentive award valued at $1,400,000 (50% stock options, 50% RSUs).
• The company highlights that EVO ICL is gaining market share from a declining laser refractive surgery market.
• Mr. Bailey's return is expected to strengthen the company's ability to execute its revenue growth strategy and accelerate innovation.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, highlighting a strategic re-engagement with a key executive and a focus on growth in a competitive market.

Positives

• Strategic re-appointment of a former CEO with deep knowledge of the company and the product category.
• David Bailey's prior tenure saw significant growth, with international revenues reaching 74% of total and ICL revenues growing to $32 million.
• EVO ICL is positioned to gain market share from a stagnating or declining laser refractive surgery market.
• Significant equity compensation package designed to incentivize performance and align with shareholder interests.
• Focus on accelerating innovation and expanding market reach into untapped populations in Asia, South America, and Africa.
• Proprietary Collamer material provides a strong competitive advantage and barriers to entry.

Negatives

• The filing is an amendment to correct an administrative error in the original filing regarding equity award allocation.
• Reliance on independent distributors in international markets.
• Potential for disruptions in the Chinese economy and global economic/geopolitical conditions.
• Exposure to fluctuations in foreign currency exchange rates and international trade disputes.
• Competition and potential losses due to product liability claims.

Risks

• Global economic and geopolitical conditions.
• Disruptions in supply chain.
• Fluctuations in foreign currency exchange rates.
• International trade disputes and tariffs.
• Competition and potential product liability claims.
• Data corruption, cyber-based attacks, or network security breaches.
• Regulatory approvals and compliance with government regulations.
• Product recalls or failures.

Future Outlook

The company anticipates that David Bailey's return will significantly strengthen its ability to execute its revenue growth strategy and accelerate its innovation roadmap, further widening its advantages over laser-based alternatives and positioning EVO ICL to become the undisputed standard of care in refractive surgery. Growth is expected in established markets and across untapped populations in South and Southeast Asia, South America, and Africa.

Management Comments

• "David Bailey doesn't just know STAAR, he helped change the trajectory of the entire phakic IOL category. As our former President and CEO, he launched commercialization of the ICL across Asia and championed development of the central port, the innovation that eliminated the need for a peripheral iridotomy and removed the single greatest barrier to phakic IOL adoption. These decisions helped set in motion what we are seeing today: EVO ICL gaining share from laser procedures, which are now stagnating or declining globally. David understands better than almost anyone what STAAR's technology is capable of, and what it will take to realize its full commercial potential. His return significantly strengthens our ability to execute on one of our three core strategic pillars Revenue Growth and to accelerate the innovation roadmap that will further widen our advantages over laser-based alternatives."
• "The opportunity in front of STAAR is as compelling as any I've seen in this industry. EVO ICL offers something laser procedures simply cannot a removable, reversible solution that preserves the natural cornea, addresses a broad spectrum of myopia and astigmatism, and sets the standard for outstanding outcomes. Laser refractive volumes are declining in every major market, and lens-based surgery is gaining ground wherever surgeons and patients understand the alternative. What makes this opportunity durable is the material at its core. Collamer is a one-of-a-kind biocompatible platform that competitors have spent decades attempting to replicate. No one has succeeded. That proprietary foundation gives EVO ICL barriers to competition that are rare in this industry, and it is precisely why the value creation opportunity ahead remains as significant as it does. The growth runway ahead is remarkable, not only in established markets like China, Japan, and the U.S., but across the large and largely untapped populations of South and Southeast Asia, South America, and Africa. And we are not standing still; our innovation roadmap has two clear objectives: first, to further expand our clinical and technical advantages over laser technologies that are, by comparison, largely static; and second, to open entirely new markets and patient populations that ICL has not yet fully reached. Both are sizeable growth drivers, and both are well underway. I'm coming back to STAAR because I believe we are at an inflection point, and that EVO ICL, powered by Collamer, is positioned to become the undisputed standard of care in refractive surgery."

Industry Context

StockSavvy.ai notes that STAAR Surgical's strategic move to re-appoint David Bailey as Chief Commercial Officer occurs as the laser refractive surgery market is experiencing stagnation or decline, while phakic IOLs, particularly their EVO ICL, are gaining traction. This suggests a market shift favoring lens-based solutions that offer reversibility and preserve corneal tissue, a trend that Bailey's leadership is expected to capitalize on.

Comparison to Industry Standards

• The filing highlights that laser refractive surgery volumes are declining in every major market, indicating a shift away from traditional laser procedures.
• EVO ICL is presented as a superior alternative due to its removability, reversibility, and preservation of the natural cornea, setting a new standard for outcomes.
• Competitors have reportedly spent decades attempting to replicate STAAR's proprietary Collamer material without success, indicating a significant technological and competitive moat.
• The company aims to further expand clinical and technical advantages over laser technologies, which are described as largely static.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased shareholder value driven by strategic leadership and expected revenue growth, supported by significant equity incentives for the new CCO.
• Employees: The appointment signals a renewed focus on commercial strategy and innovation, potentially leading to new opportunities and growth within the company.
• Surgeons and Patients: Continued development and market penetration of EVO ICL is expected to offer more advanced vision correction options, with benefits like reversibility and preservation of corneal tissue.

Next Steps

• David Bailey will join STAAR's executive committee and report to the President and CEO.
• The company will engage with ophthalmic surgeons and industry leaders at the 44th Congress of the ESCRS in London.
• Continued focus on accelerating the innovation roadmap for EVO ICL.
• Expansion into new markets and patient populations in South and Southeast Asia, South America, and Africa.

Key Dates

Recommendation

The re-appointment of a former CEO with a strong track record is a positive strategic move, and the company's positioning against a declining laser surgery market is compelling. However, the filing is primarily an executive appointment and compensation disclosure, with limited new financial data. While the outlook is positive, a 'hold' recommendation is prudent pending further financial results and execution confirmation.

Keywords

Phakic IOLs, EVO ICL, Refractive Surgery, Vision Correction, Ophthalmology, Chief Commercial Officer, Equity Awards, Market Share